Screener
4D Molecular Therapeutics FDMT Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Property and equipment, net | 13,587 | 14,867 |
| Operating lease right-of-use assets, net | 17,357 | 18,143 |
| Other assets | 9,858 | 9,188 |
| Total assets | $512,905 | $566,711 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $14,692 | $11,159 |
| Accrued and other current liabilities | 22,866 | 26,874 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's total assets?
- 4D Molecular Therapeutics (FDMT) reported total assets of $512.91M in Q1 2026.
- How has 4D Molecular Therapeutics's total assets changed year-over-year?
- 4D Molecular Therapeutics's total assets decreased by 0.5% year-over-year, from $515.73M to $512.91M.
- What is the long-term trend for 4D Molecular Therapeutics's total assets?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total assets has grown at a 14.5% compound annual growth rate (CAGR), from $288.33M to $566.71M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about 4D Molecular Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude